BerandaBT3 • FRA
add
Lineage Cell Therapeutics Inc
Tutup sebelumnya
€0,84
Rentang hari
€0,84 - €0,84
Rentang tahun
€0,33 - €1,00
Kapitalisasi pasar
230,64 jt USD
Volume Rata-Rata
377,00
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Pendapatan | 1,50 jt | 4,02% |
Biaya operasional | 5,03 jt | -2,24% |
Laba bersih | -4,14 jt | 36,73% |
Margin laba bersih | -275,57 | 39,17% |
Penghasilan per saham | -0,02 | 50,00% |
EBITDA | -6,34 jt | 2,24% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 47,90 jt | 9,82% |
Total aset | 111,75 jt | 3,01% |
Total liabilitas | 34,10 jt | -9,06% |
Total ekuitas | 77,66 jt | — |
Saham yang beredar | 228,36 jt | — |
Harga terhadap nilai buku | 2,40 | — |
Tingkat pengembalian aset | -14,46% | — |
Tingkat pengembalian modal | -20,40% | — |
Arus Kas
Perubahan kas bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Laba bersih | -4,14 jt | 36,73% |
Kas dari operasi | -4,89 jt | 15,51% |
Kas dari investasi | 1,90 jt | 5.107,89% |
Kas dari pembiayaan | 5,04 jt | -64,03% |
Perubahan kas bersih | 1,99 jt | -75,55% |
Arus kas bebas | -2,58 jt | 21,63% |
Tentang
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Didirikan
1990
Situs
Karyawan
74